Anticoagulants in Interventional Cardiology:
Overview of Anticoagulation in Interventional Cardiology
Rivaroxaban in Patients With Recent ACS: ATLAS ACS 2-TIMI 51
Apixaban After ACS: APPRAISE-2
How Do You Treat Complex Patients?
ACC/AHA Guidelines
ESC Guidelines
The Use of NOACs in the Setting of AF and PCI
AF Patients Undergoing PCI
Triple vs Dual Combination Therapy Post-PCI: WOEST Trial
New Era With NOACs: PIONEER AF-PCI Study Design
PIONEER AF-PCI: Clinically Significant Bleeding
PIONEER AF-PCI: MACE
RE-DUAL PCI: Trial Design
RE-DUAL PCI: ISTH Major or CRNM Bleeding
RE-DUAL PCI: Thromboembolic Events, Death, or Unplanned Revascularization
RE-DUAL PCI: Definite Stent Thrombosis
AUGUSTUS: Study Design
ENTRUST-AF PCI: Study Design
Antithrombotic Strategy Considerations
Antithrombotic Strategies for Complex Patients With AF Following PCI
Exploring the Use of NOACs in the Setting of TAVR
Transcatheter Aortic Valve Replacement/Implantation
Post-TAVR DAPT
Many Unknowns With TAVR
TAVR Trials
Current Guideline Recommendations for TAVR
ATLANTIS Trial: Apixaban vs Standard of Care
GALILEO Trial Design: Rivaroxaban vs Clopidogrel
ENVISAGE-TAVI: Edoxaban- vs VKA-Based Regimen
Interim Treatment Suggestions Until More Data Become Available for TAVR Patients
Transitioning Care From Post-Procedure to Long-Term Management
Follow-Up Considerations
Different Durations of Therapy Patient Scenarios
Patient Anticoagulation Education
NOAC Antidotes
Conclusion
Abbreviations
Abbreviations (cont)
Abbreviations (cont)